Sino Biopharmaceutical's (HKG:1177) TQB2101 anti-tumor obtained Chinese implied approval for clinical trials, according to a Thursday filing with the Hong Kong bourse.
The drug showed anti-tumor activity in receptor tyrosine kinase-like orphan receptor-1-positive tumor models during preclinical studies, the filing said.
ROR-1 is seen in lung, pancreatic, breast, colorectal, and ovarian cancers, the filing said.
Separately, China's medical products administrator accepted Sino Biopharm's clinical trial application for its TQB6411 anti-lung cancer drugs.
The drug targets the epidermal growth factor receptor and cell mesenchymal epithelial transition present as lung cancer driver genes, according to a separate Thursday filing.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.